Ant Group has acquired Haodf Online

Recently, the Internet medical enterprise GoodThe operating entity of Doctor Online —— Interactive Peak Technology (Beijing) Co., Ltd. underwent a change in its business registration.The company's shareholder has changed to Shanghai Yunyang Enterprise Management Consulting Co., Ltd., a subsidiary of Ant Group, with a 100% stake; shareholders such as Wang Hang, the founder of Haodf.com, and Lei Jun have exited, but Wang Hang still serves as the chairman of the board;The legal representative of the company has been changed to Zhang Junjie, Vice President of Alipay and General Manager of the Digital Medical Health Division.。
This change in business registration information marks the first time definitive public information has been disclosed. As of now, neither Haodaifu Online nor Alipay has made any proactive public statements.

Fosun Pharmaceutical Invests $37 Million to Gain Controlling Stake in Fosun Kite

September 13, 2024Fosun Pharmaceutical's subsidiary, Fosun Pharmaceutical Industry, plans to pay $27 million in cash to acquire 50% of Fosun Kite's equity held by Kite Pharma.Upon completion of the transfer, Fosun Pharmaceutical will hold 100% equity interest in Fosun Kite and plans to make a cash contribution of 10 million US dollars or an equivalent amount in RMB as the sole shareholder to increase the capital of Fosun Kite.

At the same time, Fosun KiteLicensed by Kite Pharma in the region(i.e., Mainland China, Hong Kong, and Macao)And Fields(Cancer Treatment Field)Exclusive development, production, and commercialization of Yikaida® and Brexu-Cel in China(Fosun Kite's R&D project FKC889)The Right。

In addition, a wholly-owned subsidiary of Fosun PharmaceuticalFosun Kite to be renamed as Fosun Karry, and will serve as the core platform for Fosun Pharmaceutical's cell therapy technology, continuing to focus on the field of tumor immunotherapy and promoting CAR-T cell therapy products to benefit more patients.

Taimei Medical Launches PDIE, Passes Hong Kong Stock Exchange Listing Hearing

Taimei Medical will kick off its PDIE (Pre-Deal Investor Education) on September 18, with the goal of officially listing on the Hong Kong Stock Exchange in early Q4 this year., CICC and Morgan Stanley as joint sponsors. Previously, Taimei MedicalPassed the listing hearing of the Hong Kong Stock Exchange on September 16。

35% of the proceeds from Taimei Medical's Hong Kong IPO will be used to optimize and upgrade the TrialOS and PharmaOS platforms, as well as their corresponding cloud-based software and digital services; approximately 30% will be allocated to enhancing the company’s core technologies and R&D capabilities, including the development of AI and big data technologies, IT infrastructure, and low-code development. Additionally, the company plans to use the remaining funds to strengthen marketing capabilities, execute strategic acquisitions, and supplement working capital.

Health Road Files for IPO with HKEX Again

On September 13, 2024, the HKEX website showed,Fujian Health Road Information Technology Co., Ltd. Submits HKEX Listing Application Again, CCB International is the sole sponsor. According to Frost & Sullivan, as of December 31, 2023, based on the number of registered individual users on our platform,Health Road operates one of the largest digital health and medical service platforms in China.

Health Road has completed multiple rounds of financing exceeding 5.5 billion yuan, with its Series A round reaching up to 60 million US dollars, invested by Baidu. As of the date of the signing of the prospectus, Mr. Zhang Wanneng and Fengji are considered the controlling shareholders of Health Road.

AIVF Hospital Submits Application to HKEX Again

Research and Development Progress

Merck/Daiichi Sankyo HER3 ADC Treatment for EGFR-Mutant NSCLC Phase III Study Meets Primary PFS Endpoint

On September 17, Merck and Daiichi Sankyo announced,Patritumab Deruxtecan (HER3-DXd) in the Treatment of Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with EGFR-TKI: The Phase III HERTHENA-Lung02 Study Met the Primary Endpoint of Progression-Free Survival (PFS).

Compared with pemetrexed maintenance chemotherapy after induction chemotherapy combined with platinum and pemetrexed, patients treated with patritumab deruxtecan achieved a significant statistical improvement in PFS. At the time of analysis, data for the secondary endpoint overall survival (OS) were not yet mature, and the trial will continue to further evaluate OS.

Hengrui's New ADC Submits for Marketing Authorization Application

Recently, Suzhou Shengdiya Biopharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received the "Acceptance Notice" issued by the National Medical Products Administration.The marketing authorization application for the company's Recombinant Trastuzumab Injection (R&D code: SHR-A1811) has been accepted by the National Medical Products Administration, and recently, the product has been included in the priority review process.. The indications for this product are: for the treatment of adult patients with locally advanced or metastatic HER2-mutant non-small cell lung cancer who have previously received at least one systemic therapy.

Recombinant Trastuzumab Injection isHengrui Medicine's self-developed antibody-drug conjugate targeting HER2, intended for the treatment of advanced solid tumors with HER2 expression or mutation.。 

Qilu Pharmaceutical's Semaglutide Similar Drug Submitted for Market Approval

September 15, 2024Qilu Pharmaceutical's Semaglutide Similar Drug Marketing Application Accepted by NMPA; This is the Third Semaglutide Similar Drug Marketing Application in China。 

On April 2, 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. submitted the marketing application for Semaglutide Injection (brand name: Jiutai) and it was accepted. The indication is for glycemic control in adult patients with type 2 diabetes. This is the first Semaglutide biosimilar to be submitted for marketing in China. On June 12, 2024, Livzon Pharmaceutical's Semaglutide biosimilar also submitted a marketing application, making it the second in China.

Lilly's Heavyweight New Drug "Tirzepatide" New Indication Submitted for Marketing in China

On September 15, the latest announcement on the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) revealed,Eli Lilly and Company's Heavyweight Drug, the GIP/GLP-1 Receptor Dual Agonist Tirzepatide Injection, Receives Acceptance for New Indication Marketing Application, specific indications have not been disclosed. This isTirzepatide's Third Marketing Application Submission in China. 

Industry insiders speculate that the indication for this marketing application may beImproving Snoring Conditions in Obese Patients with Moderate to Severe Obstructive Sleep Apnea (OSA)Lilly has already submitted an application to the FDA for this indication. In addition, the international multi-center (including China) Phase 3 clinical study of tirzepatide for heart failure with preserved ejection fraction in patients with comorbid obesity has also been completed.

Industry Trends

NMPA: Encourage Import Drugs to China!

On September 17, at the press conference on the theme of "Promoting High-Quality Development" held by the State Council Information Office, Li Li, director of the National Medical Products Administration, stated at the meeting:

1、Support Open Cooperation in the Pharmaceutical Industry, Strengthen the transformation and implementation of internationally recognized regulatory rules in China, and support the conduct of international multicenter clinical trials,Promote the simultaneous R&D, simultaneous submission, simultaneous review, and simultaneous market launch of global drugs in China。

2、Explore the Segmented Production Model of Biologics, and pilot the segmented production of innovative and clinically urgently needed biologics in some regions.

3. Increase support for the import and export of pharmaceuticals trade,Accelerate the approval process for new drugs already marketed overseas to be launched domestically, and encourage multinational companies to transfer the production of original chemical drugs, biologics, and high-end medical equipment to China.. Improve the relevant policies for drug export sales certificates, encourage more pharmaceutical enterprises in our country to go global and participate in international trade, so that Chinese drugs can benefit all humanity.

Wuxi, Jiangsu Establishes Special Fund for Biomedical Industry

Recently, JiangWuxi Biomedical Industry Special Fund (Limited Partnership) Established, with Wuxi Zhanxin Private Equity Fund Management Co., Ltd. as the General Partner, and a Capital Contribution of 4 Billion Yuan。。

The fund is financed 25% by the Jiangsu Provincial Mother Fund and 75% by Wuxi City; it has a term of 15 years, including an 8-year investment period and a 7-year exit period. The fund adopts a "sub-fund + direct investment" approach, primarily investing in fields such as innovative drugs, high-end active pharmaceutical ingredients, traditional Chinese medicine, cell and gene therapies, medical devices, medical support industries, consumer healthcare, and improvements in national health quality.

—END—

Highlights:

Another Innovative Pharmaceutical Company Goes Public, Stock Price Surges Over 28%

Junshi Biosciences Narrows Losses, Are Chinese Innovative Drug Companies Reaching a Profit Turning Point?

List of Listed Traditional Chinese Medicine Enterprises: 17 Achieve Double Growth, Six Giants' Net Profit Exceeds 1 Billion

World's First! China-Made "Million-Dollar Cancer Drug" Approved, with $1 Billion in Sales Expected Within the Year